The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase I study of the CDK4/6 inhibitor, palbociclib plus 5-fluorouracil (5FU) in patients with advanced solid tumor malignancies (NCT01522989).
 
Michael J. Pishvaian
Stock and Other Ownership Interests - Perthera
Honoraria - Caris Life Sciences; Celgene; Sirtex Medical
Consulting or Advisory Role - Caris Life Sciences; Celgene; Perthera; Sirtex Medical
Research Funding - Celldex (Inst); Daiichi Sankyo (Inst); Genentech (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); MedImmune (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Regeneron (Inst)
Travel, Accommodations, Expenses - Caris Life Sciences; Perthera; Sirtex Medical
 
Hongkun Wang
No Relationships to Disclose
 
Brandon George Smaglo
Honoraria - Boston Biomedical
Consulting or Advisory Role - Five Prime Therapeutics
Speakers' Bureau - Taiho Pharmaceutical
Research Funding - Novartis (Inst)
 
Jennifer Gao
Employment - WorldCare Clinical, LLC
Research Funding - Genentech/Roche
 
Laura Macke
No Relationships to Disclose
 
Erica Redmond
No Relationships to Disclose
 
Eva Camilla Andersson Permaul
No Relationships to Disclose
 
Supti Sen
No Relationships to Disclose
 
Damian L. McCarthy
No Relationships to Disclose
 
Bhaskar Kallakury
No Relationships to Disclose
 
Stephen V. Liu
Consulting or Advisory Role - AstraZeneca; Biodesix; Boehringer Ingelheim; Genentech; Perthera
 
Aiwu Ruth He
Speakers' Bureau - Bayer
Research Funding - Lilly (Inst); Pfizer (Inst)
 
Jimmy J. Hwang
Consulting or Advisory Role - Amgen; Bayer; Genentech/Roche; Lilly; Merrimack; Sanofi; Taiho Pharmaceutical
Speakers' Bureau - Amgen; Bayer/Onyx; Genentech/Roche
Expert Testimony - Roche
 
Sandra M. Swain
Honoraria - Clinigen Group; Roche
Consulting or Advisory Role - Clinigen Group; Genentech/Roche
Research Funding - Genentech; Puma Biotechnology; Roche
Travel, Accommodations, Expenses - Genentech/Roche
 
John Marshall
Honoraria - Amgen; Bayer/Onyx; Boehringer Ingelheim; Daiichi Sankyo; Genentech/Roche
Consulting or Advisory Role - Amgen; Bayer/Onyx; Boehringer Ingelheim; Daiichi Sankyo; Genentech/Roche
Speakers' Bureau - Amgen; Bayer/Onyx; Genentech/Roche
Research Funding - Amgen (Inst); Bayer/Onyx (Inst); Boehringer Ingelheim (Inst); Genentech/Roche (Inst); MedImmune (Inst); Pfizer (Inst)
 
Paula Raffin Pohlmann
Leadership - Immunonet BioSciences
Stock and Other Ownership Interests - Immunonet BioSciences
Consulting or Advisory Role - Immunonet BioSciences; OncoPlex Diagnostics; Personalized Cancer Therapy
Patents, Royalties, Other Intellectual Property - IMMUNOLOGICAL COMPOSITIONS AS CANCER BIOMARKERS AND/OR THERAPEUTICS; U.S. Patent and Trademark Office No. US 20120201820. Invention title: Immunological Compositions as Cancer Therapeutics.